Anna Potamianou

1.5k total citations
37 papers, 716 citations indexed

About

Anna Potamianou is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hematology. According to data from OpenAlex, Anna Potamianou has authored 37 papers receiving a total of 716 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 10 papers in Hematology. Recurrent topics in Anna Potamianou's work include Cancer Treatment and Pharmacology (10 papers), Multiple Myeloma Research and Treatments (7 papers) and Colorectal Cancer Treatments and Studies (6 papers). Anna Potamianou is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), Multiple Myeloma Research and Treatments (7 papers) and Colorectal Cancer Treatments and Studies (6 papers). Anna Potamianou collaborates with scholars based in Greece, France and United States. Anna Potamianou's co-authors include Vassilis Georgoulias, Αthanasios Kotsakis, George Samonis, Nikolaos Ziras, Aris Polyzos, K. Syrigos, J. Boukovinas, Pavlos Papakotoulas, G. Stathopoulos and J. Varthalitis and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Cancer.

In The Last Decade

Anna Potamianou

30 papers receiving 690 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anna Potamianou Greece	13	481	198	196	142	118	37	716
Jacques Camerlo France	18	448 0.9×	190 1.0×	212 1.1×	162 1.1×	172 1.5×	50	932
David Topolsky United States	15	348 0.7×	127 0.6×	337 1.7×	123 0.9×	83 0.7×	39	884
Jonathan C. Yau United States	17	454 0.9×	144 0.7×	190 1.0×	197 1.4×	128 1.1×	33	768
Tomáš Skácel Switzerland	16	819 1.7×	86 0.4×	343 1.8×	249 1.8×	281 2.4×	33	1.0k
Senthil Rajappa India	16	286 0.6×	68 0.3×	146 0.7×	184 1.3×	139 1.2×	87	730
Riikka Räty Finland	18	731 1.5×	143 0.7×	174 0.9×	187 1.3×	234 2.0×	46	1.3k
A.K. Kakkar United Kingdom	13	273 0.6×	150 0.8×	376 1.9×	120 0.8×	269 2.3×	28	1.0k
Raja Pramanik India	14	222 0.5×	81 0.4×	89 0.5×	126 0.9×	165 1.4×	95	574
Virginie Lucas United States	13	779 1.6×	92 0.5×	67 0.3×	235 1.7×	130 1.1×	24	1.1k
N. J. Vogelzang United States	16	302 0.6×	89 0.4×	75 0.4×	290 2.0×	286 2.4×	38	759

Countries citing papers authored by Anna Potamianou

Since Specialization

Citations

This map shows the geographic impact of Anna Potamianou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Potamianou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Potamianou more than expected).

Fields of papers citing papers by Anna Potamianou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Potamianou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Potamianou. The network helps show where Anna Potamianou may publish in the future.

Co-authorship network of co-authors of Anna Potamianou

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Potamianou. A scholar is included among the top collaborators of Anna Potamianou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Potamianou. Anna Potamianou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mateos, María‐Victoria, Katja Weisel, Valerio De Stefano, et al.. (2021). LocoMMotion: A prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed/refractory multiple myeloma (RRMM) receiving ≥3 prior lines of therapy.. Journal of Clinical Oncology. 39(15_suppl). 8041–8041. 4 indexed citations

Fenaux, Pierre, Valeria Santini, Maria Antonietta Aloe Spiriti, et al.. (2018). A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS. Leukemia. 32(12). 2648–2658. 99 indexed citations

Dimopoulos, Meletios Α., Robert Z. Orlowski, Pieter Sonneveld, et al.. (2014). Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. Haematologica. 100(1). 100–106. 23 indexed citations

Macdougall, Iain C., Nicole Casadevall, Francesco Locatelli, et al.. (2014). Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS). Nephrology Dialysis Transplantation. 30(3). 451–460. 52 indexed citations

Dimopoulos, Meletios Α., Robert Z. Orlowski, Thierry Façon, et al.. (2013). Retrospective Matched-Pair Analysis Of The Efficacy and Safety Of Bortezomib Plus Dexamethasone Versus Bortezomib Monotherapy In Patients (Pts) With Relapsed Multiple Myeloma (MM). Blood. 122(21). 3177–3177. 2 indexed citations

Mystakidou, Kyriaki, Anna Potamianou, & Eleni Tsilika. (2007). Erythropoietic growth factors for children with cancer: a systematic review of the literature. Current Medical Research and Opinion. 23(11). 2841–2847. 1 indexed citations

Ignatiadis, Michail, Aris Polyzos, George P. Stathopoulos, et al.. (2006). A Multicenter Phase II Study of Docetaxel in Combination with Gefitinib in Gemcitabine-Pretreated Patients with Advanced/Metastatic Pancreatic Cancer. Oncology. 71(3-4). 159–163. 39 indexed citations

Ziras, Nikolaos, Anna Potamianou, Ioannis Varthalitis, et al.. (2006). Multicenter Phase II Study of Gemcitabine and Oxaliplatin (GEMOX) as Second-Line Chemotherapy in Colorectal Cancer Patients Pretreated with 5-Fluorouracil plus Irinotecan. Oncology. 70(2). 106–114. 18 indexed citations

Kakolyris, Stylianos, K. Kalbakis, Anna Potamianou, et al.. (2006). Salvage Chemotherapy with Gemcitabine and Oxaliplatin in Heavily Pretreated Patients with Metastatic Breast Cancer: A Multicenter Phase II Study. Oncology. 70(4). 273–279. 6 indexed citations

10.

Stathopoulos, G., K. Syrigos, Gerasimos Aravantinos, et al.. (2006). A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. British Journal of Cancer. 95(5). 587–592. 167 indexed citations

11.

Mavroudis, D., Alexandros Ardavanis, Ioannis Boukovinas, et al.. (2006). A multicenter randomized study comparing vinorelbine plus gemcitabine versus capecitabine monotherapy as salvage treatment in patients with advanced breast cancer pretreated with taxane and anthracycline chemotherapy: A preliminary report. Journal of Clinical Oncology. 24(18_suppl). 658–658. 13 indexed citations

12.

Potamianou, Anna, Nikolaos Androulakis, Pavlos Papakotoulas, et al.. (2005). Sequential Combination of Paclitaxel-Carboplatin and Paclitaxel-Liposomal Doxorubicin as a First-Line Treatment in Patients with Ovarian Cancer. Oncology. 69(4). 348–353. 9 indexed citations

13.

Syrigos, Konstantinos, et al.. (2005). Phase I trial of weekly docetaxel with a 4-weekly cisplatin administration in patients with advanced gastric carcinoma. Cancer Chemotherapy and Pharmacology. 55(5). 466–470. 9 indexed citations

14.

Androulakis, Nikolaos, J. Boukovinas, Sofia Agelaki, et al.. (2005). Docetaxel, cisplatin and gemcitabine as first line for patients with advanced/metastatic head and neck cancer. Journal of Clinical Oncology. 23(16_suppl). 5586–5586. 3 indexed citations

15.

Georgoulias, Vassilis, K. Syrigos, M. Agelidou, et al.. (2005). Docetaxel in combination with gemcitabine (DG) versus docetaxel (D) as front-line treatment in patients with advanced/metastatic NSCLC: A multicentre, randomized, phase III trial. Journal of Clinical Oncology. 23(16_suppl). 7052–7052. 3 indexed citations

16.

Souglakos, John, Konstantinos Syrigos, Anna Potamianou, et al.. (2004). Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial. Annals of Oncology. 15(8). 1204–1209. 41 indexed citations

17.

Lord, Joanne, et al.. (2004). Cost of home palliative care compared with conventional hospital care for patients with haematological cancers in Greece. The European Journal of Health Economics. 6(2). 102–106. 9 indexed citations

18.

Mavroudis, Dimitriοs, A. Alexopoulos, Nikolaos Ziras, et al.. (2000). Front-line treatment of advanced breast cancer with docetaxel and epirubicin: A multicenter phase II study. Annals of Oncology. 11(10). 1249–1254. 27 indexed citations

19.

Kouroussis, Ch., Anna Potamianou, T. Giannakakis, et al.. (1999). Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: A multicenter dose-escalation study. Annals of Oncology. 10(5). 547–552. 33 indexed citations

20.

Mavroudis, Dimitriοs, Nikolaos Malamos, A. Alexopoulos, et al.. (1999). Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: A multicenter phase II trial. Annals of Oncology. 10(2). 211–216. 86 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact